


Cancer Cell

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

Graphical Abstract



Authors

Eric F. Zhu, Shuning A. Gai, ..., Glenn Dranoff, K. Dane Wittrup

Correspondence

wittrup@mit.edu

In Brief

Zhu et al. find that combining an anti-tumor antigen antibody and an IL-2 fusion protein that has delayed systemic clearance controls tumor growth in animal models via a concerted innate and adaptive immune response. Adoptive transfer of anti-tumor T cells together with this combination leads to long-term efficacy.

Highlights

- Serum-persistent IL-2 and anti-tumor IgG induces strong control of tumor growth
- Immune response includes a cytokine storm with high levels of MIP-2, IFN γ , and IL-6
- Neutrophils drive efficacy, and infiltration is mediated by NK cells and macrophages
- Adoptive transfer of CD8⁺ T cells, Fc/IL-2, and antibody confers long-term efficacy



Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

Eric F. Zhu,^{1,5,12} Shuning A. Gai,^{1,5,12} Cary F. Opel,^{1,5,12} Byron H. Kwan,^{2,5} Rishi Surana,⁶ Martin C. Mihm,^{7,9} Monique J. Kauke,^{1,5} Kelly D. Moynihan,^{2,5} Alessandro Angelini,⁵ Robert T. Williams,³ Matthias T. Stephan,^{4,5} Jacob S. Kim,⁵ Michael B. Yaffe,^{2,3,5} Darrell J. Irvine,^{2,4,5,10,11} Louis M. Weiner,⁶ Glenn Dranoff,⁸ and K. Dane Wittrup^{1,2,5,*}

¹Department of Chemical Engineering

²Department of Biological Engineering

³Department of Biology

⁴Department of Materials Science and Engineering

⁵Koch Institute for Integrative Cancer Research

Massachusetts Institute of Technology, Cambridge, MA 02139, USA

⁶Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA

⁷Department of Pathology

⁸Department of Medical Oncology, Dana-Farber Cancer Institute

Harvard Medical School, Boston, MA 02115, USA

⁹Department of Pathology, Massachusetts General Hospital, Boston, MA 02214, USA

¹⁰Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA 02129, USA

¹¹Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

¹²Co-first author

*Correspondence: wittrup@mit.edu

<http://dx.doi.org/10.1016/j.ccell.2015.03.004>

SUMMARY

Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody and an untargeted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive isogenic tumor models via a concerted innate and adaptive response involving neutrophils, NK cells, macrophages, and CD8⁺ T cells. This combination therapy induces an intratumoral “cytokine storm” and extensive lymphocyte infiltration. Adoptive transfer of anti-tumor T cells together with this combination therapy leads to robust cures of established tumors and development of immunological memory.

INTRODUCTION

The compelling promise of immunotherapies is to counter heterogeneously mutating tumors with the adaptive immune response. In particular, the benefits of combining multiple therapies are particularly appealing (van Elsas et al., 1999; Overwijk, 2005; Stagg et al., 2007). One of the earliest such combinations tested was the cytokine interleukin-2 (IL-2) together with monoclonal antibodies against tumor antigens.

Antibodies such as trastuzumab, rituximab, and cetuximab have achieved tremendous clinical successes (Weiner et al., 2009), and their capability to enlist innate effector functions is a critical component of their therapeutic efficacy (Ferris et al., 2010). In mechanistic studies in xenograft mouse models, innate effector cells expressing activating FcγR, particularly natural killer (NK) cells, have been shown to be required for the therapeutic efficacy of monoclonal antibodies (Clynes et al., 2000; Sliwkowski et al., 1999), and lymphoma patients expressing higher-affinity alleles of FcγRIII responded better to rituximab

Significance

Weekly intravenous administration of two proteins—an anti-tumor antigen antibody and an IL-2 fusion protein with extended serum half-life—significantly increases tumor infiltration of neutrophils, NK cells, macrophages, and CD8⁺ T cells and controls the growth of aggressive isogenic tumors. Our work supports a paradigm of stimulating concerted anti-tumor action from both adaptive and innate immunity to achieve durable tumor control.

therapy (Weng and Levy, 2003), consistent with a major contribution of antibody-dependent cell-mediated cytotoxicity (ADCC) to antibody therapy. Encouragingly, cell culture bioassay studies have demonstrated that IL-2 enhanced NK cell activity against antibody-coated tumor cells (Carson et al., 2001; Eisenbeis et al., 2004). Unfortunately, these results did not translate clinically because such combinations consistently failed to provide significant clinical benefits over antibody alone (Khan et al., 2006; Mani et al., 2009; Poiré et al., 2010).

T cells play an unexpectedly critical role in anti-tumor antigen antibody therapy, although their importance is often not observed because of studies being performed in immunodeficient mice. In studies of antibody therapy in immunocompetent mice with isogenic tumors, therapeutic effects vanish when CD8⁺ T cells are depleted (Abès et al., 2010; Dyllal et al., 1999; Park et al., 2010; Stagg et al., 2011; Vasović et al., 1997; Wang et al., 2012). We imagined that IL-2 treatment might be exploited to amplify monoclonal antibody therapy not simply via the previously assumed NK-mediated ADCC but also by boosting the CD8⁺ T cell adaptive response because IL-2 exerts significant pleiotropic effects on regulatory, helper, and cytolytic memory T cells (Liao et al., 2013).

However, given the poor clinical results of combining IL-2 with monoclonal antibodies, we hypothesized that the signaling resulting from parenteral IL-2 administration may be temporally limited because IL-2 is rapidly cleared when administered intravenously in bolus doses (Konrad et al., 1990), leading to highly oscillatory cytokine exposure. The cellular response to such IL-2 spikes can be dramatically different than the response to more stable concentration trajectories (Rao et al., 2005). Both the duration and strength of IL-2 signaling determine the balance between effector and memory cytolytic T cell development (Feau et al., 2011; Kalia et al., 2010; Pipkin et al., 2010), a balance critical to the success of immunotherapies such as adoptive cell therapy (June, 2007). It is noteworthy that, in previous clinical trials combining IL-2 and antibodies, IL-2 was administered as a subcutaneous low-dose pulse either once per day (Mani et al., 2009; Poiré et al., 2010) or three times per week (Khan et al., 2006). Consequently, these patients' T cells were exposed to short bursts of IL-2 signaling. Therefore, we sought to develop a means by which sufficiently sustained IL-2 signaling could be provided so that simultaneous dosing with an anti-tumor antigen monoclonal antibody might provide the synergistic therapeutic effect that has so far remained elusive.

RESULTS

Extending IL-2 Serum Exposure via Multiple Injections

To explore the effects of differing IL-2 exposure combined with a monoclonal antibody targeting a tumor antigen, we first treated established B16F10 melanoma with IL-2 or the anti-TYRP-1 antibody TA99. TYRP-1 is a melanocyte marker that becomes surface-expressed on B16F10. With infrequent IL-2 exposure, neither agent, dosed separately or together, provided survival benefits (Figure 1A). However, when extended daily dosing was performed, a notable synergistic effect was observed when TA99 was added, significantly extending survival (Figure 1B). Despite this promising response, daily IL-2 dosing resulted in poor body condition for many of the treated mice (data not

shown), and such a regimen could be arduous and expensive for clinical translation. Therefore, we sought to achieve similar synergistic effects through a form of IL-2 that provides similar long-term IL-2 exposure but requires fewer and smaller doses.

Extending IL-2 Circulation Lifetime via Fc Fusion

To increase the persistence of IL-2 exposure in vivo, we fused wild-type murine IL-2 to the fragment crystallizable (Fc) region of murine immunoglobulin G2a (IgG2a), termed Fc/IL-2 (Figure S1A). We introduced the D265A mutation to the Fc—shown previously to abrogate Fc γ R binding and complement activation (Baudino et al., 2008)—to eliminate cytotoxic effects on the IL-2R⁺ cells we wished to stimulate. We chose a monovalent heterodimeric form of the fusion protein to avoid avidity effects from two IL-2 molecules on the same protein. Fc/IL-2 possessed a similar specific bioactivity as murine IL-2 produced either from *E. coli* or the clinical drug Proleukin (Figure S1B). Fc/IL-2 demonstrated an increase in serum duration, with a β half-life nearly three times that of wild-type murine IL-2 (Figure S1C; Table S1). Fc/IL-2 exhibited significant degradation after in vitro incubation in serum at 37°C for 48 hr (Figure S1D).

Fc/IL-2 and TA99 Synergize to Control B16F10 Growth

We proceeded to evaluate the efficacy of Fc/IL-2 against established B16F10 tumors and its potential synergism with TA99. Cohorts were administered equimolar Fc/IL-2 to that of the IL-2 given in the infrequent exposure case with identical dosing schedules. Impressively, administration of Fc/IL-2 with TA99 (Fc/IL-2+TA99) resulted in a strong synergy between the two agents that fully controlled B16F10 growth during treatment, extending survival further than either single agent (Figure 1C). The dosing of Fc/IL-2+TA99 appeared well tolerated by the mice, which continued to gain weight during treatment (Figure S1E) and showed no changes in pulmonary wet weight (Figure S1F), although splenomegaly (Figure S1G) and an acute increase in the serum level of liver enzymes (Figure S1H) and various inflammatory cytokines (Figure S1I) were observed.

To confirm that the synergistic efficacy was solely due to the serum half-life extension of Fc/IL-2 as opposed to immunological effects conferred by the Fc region, we fused IL-2 to mouse serum albumin (MSA/IL-2) to generate an alternative form of IL-2 with an extended serum half-life (Figure S1C; Table S1) and bioactivity (Figure S1B) because albumin is similarly recycled by FcRn (Anderson et al., 2006). MSA/IL-2+TA99 and Fc/IL-2+TA99 were essentially identical in efficacy (Figure 1D), suggesting that any form of IL-2 with an increased serum half-life, or perhaps a continuous infusion of IL-2, will exhibit this synergistic therapeutic effect.

We further tested three additional tumor models with three different monoclonal antibodies to demonstrate the generalizability of this strategy: (1) D5-HER2 melanoma in hmHER2 transgenic mice (Wang et al., 2012) using Fc/IL-2 and trastuzumab (Herceptin) (Figure 2A); (2) RM9 prostate cancer (Baley et al., 1995) in C57BL/6 mice using Fc/IL-2 and 3F8 monoclonal antibody (mAb) (Zhang et al., 1998), a murine IgG3 antibody targeting the GD2 antigen expressed on RM9 (Figure 2B); and (3) Ag104A fibrosarcoma in C3H/HeN mice using Fc/IL-2 and 237 mAb, a murine IgG2a targeting the OTS8 antigen found on Ag104A (Ward et al., 1989; Figure 2C).




Figure 1. Extended Serum Half-Life IL-2 Combined with a Tumor-Specific Antibody Controls Tumor Growth

(A–D) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous B16F10 tumors treated with (A) PBS, murine IL-2, and/or TA99; (B) PBS, Proleukin, and/or TA99; (C) PBS, Fc/IL-2, and/or TA99; and (D) PBS, Fc/IL-2+TA99, or MSA/IL-2+TA99. Arrows indicate points of treatment. $n = 5/\text{group}$. * $p < 0.05$, ** $p < 0.01$ versus the corresponding color group in the legend. Data are mean \pm SEM.

See also [Figure S1](#) and [Table S1](#).

2+TA99 treatment resulted in brisk lymphocyte infiltration both at the periphery ([Figure S2Ad](#)) and within the tumor mass ([Figure S2B](#)) as well as widespread necrosis ([Figure S2C](#)). Additionally, we observed instances of direct lymphocyte engagement with a tumor cell ([Figure S2B](#)). Similarly, immunofluorescence of tumor sections showed robust infiltration of these immune cells ([Figure 3A](#)).

It has been reported previously that the presence of briskly infiltrating lymphocytes is a favorable prognostic indicator in melanoma ([Clemente et al., 1996](#)). This apt observation prompted us to further identify and quantify infiltrating effector cells using flow cytometry. The $\text{CD3}^+\text{CD8}^+$ T cell population was increased significantly more than 10-fold with Fc/IL-2 or Fc/IL-2+TA99 ([Figure 3B](#)). The $\text{CD3}^+\text{CD4}^+$ T cell and $\text{CD3}^+\text{CD4}^+\text{CD25}^+\text{FoxP3}^+$ regulatory T (T_{reg}) cell population were elevated with all three treatment groups ([Figure 3B](#)). As expected of an IL-2-based therapy, the increase in T_{reg} cells was proportional to that of CD8^+ T cells because the ratio of these two cells was unaffected ([Figure S2D](#)). The $\text{CD3}^-\text{NK1.1}^+$ NK cell population was also increased significantly more

In every case, the combination of Fc/IL-2 with an anti-tumor IgG showed superior efficacy to either agent alone, even where the antibody itself provided no benefits ([Figure 2](#)). Therefore, the strong tumor-suppressive effect is generalized to four different tumor models with a unique anti-tumor antigen and antibody pairing plus a serum-persistent form of IL-2.

Fc/IL-2+TA99 Promotes Effector Cell Infiltration

We hypothesized that the strong control of tumor growth observed was due to a combination of adaptive and innate immune activation localized to the tumor microenvironment. H&E staining of tumor sections from mice treated with either Fc/IL-2 or TA99 alone showed some lymphocyte infiltration restricted to the edges ([Figures S2Ab](#) and [S2Ac](#)). However, Fc/IL-

than 5-fold with Fc/IL-2 or Fc/IL-2+TA99 ([Figure 3B](#)). Interestingly, an increase in the $\text{CD11b}^+\text{Ly-6C}^+\text{Ly-6G}^+$ neutrophil population was unique to the combination of Fc/IL-2+TA99 ([Figure 3B](#)), and only Fc/IL-2+TA99 showed a statistically significant difference in the $\text{CD11b}^+\text{F4/80}^+$ macrophage population relative to the PBS-treated control ([Figure 3B](#)).

We next sought to determine the contribution of distinct effectors to therapeutic efficacy through antibody-mediated depletions, where confirmation of systemic depletion was obtained using samples from the spleen, blood, or peritoneal cavity ([Figure S2E](#)). CD8^+ T cell depletion, neutrophil depletion, or NK cell depletion all attenuated therapeutic efficacy, suggesting an important role for each of these cell types in controlling tumor growth ([Figure 3C](#)). Depletion of the tumor-resident




Figure 2. Extended Serum Half-Life IL-2 Combined with a Tumor-Specific Antibody Is Generalizable

(A) Tumor growth and survival curves of hmHER2 Tg mice bearing subcutaneous D5-HER2 tumors treated with PBS, Fc/IL-2, and/or Herceptin. n = 10/group.

(B) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous RM9 tumors treated with PBS, Fc/IL-2, and/or 3F8 mAb. n = 5/group.

(C) Tumor growth and survival curves of C3H mice bearing subcutaneous Ag104A tumors treated with PBS, Fc/IL-2, and/or 237 mAb. n = 5/group.

*p < 0.05, **p < 0.01, ****p < 0.0001 versus the corresponding color group in the legend. Data are mean ± SEM.

ure 4A), an observation consistent with the observed increase in neutrophil infiltration (Figure 3B), because MIP-2 is a powerful neutrophil attractant (Wolpe et al., 1989).

We next wished to understand how the antibody TA99 was able to drastically improve the mild efficacy of Fc/IL-2 alone. Fc/IL-2 or Fc/IL-2+TA99 induced nearly equivalent intratumoral levels of many different cytokines and chemokines, but there were eight different cytokines and chemokines that appeared to be elevated in the tumor only with Fc/IL-2+TA99 treatment (Figure 4B, blue). These included inflammatory cytokines such as IL-6, IL-1 α ,

CD11b⁺F4/80⁺ macrophage population by an anti-CSF-1R antibody had no apparent effect on the efficacy of the treatment (Figure S2F). Nevertheless, this population might simultaneously contribute to and hinder the therapeutic effect via a mix of “M1 anti-tumor” or “M2 pro-tumor” macrophages, respectively. To briefly investigate this, we looked at the macrophage polarization through the ratio of CD206 and major histocompatibility complex class II (MHC-II) expression (Gabilovich et al., 2012), indicative of macrophages tending toward M2 or M1 polarization, respectively. This ratio was slightly lower in Fc/IL-2+TA99-treated tumors but not statistically significant (Figure S2G).

Fc/IL-2+TA99 Promotes an Intratumoral Cytokine Storm with NK Cells Inducing Macrophage-Derived MIP-2

Given the extensive intratumoral immune cell infiltration with Fc/IL-2+TA99, we explored changes in intratumoral cytokine and chemokine levels induced by these infiltrating effector cells through multiplex Luminex assays. Nearly all cytokines and chemokines measured exhibited significant increases in intratumoral concentration when tumor-bearing mice were treated with Fc/IL-2+TA99 relative to PBS (Figure 4A). The set of elevated cytokines observed in our system broadly overlaps with those seen in the clinical presentation of a “cytokine storm” (Suntharalingam et al., 2006; Winkler et al., 1999), indicative of a broad and strong immune activation within the tumor. The CXCR2 ligand MIP-2 (CXCL2) showed a striking increase of nearly 40-fold (Fig-

and IL-1 β but also neutrophil-related factors such as granulocyte colony-stimulating factor (G-CSF) and MIP-2 (Figure 4B). These results further suggest the importance of neutrophils in the therapeutic efficacy of Fc/IL-2+TA99 and highlight that this synergistic effect is only achieved with the two agents together.

To further understand which cells might be mediating these different cytokines, we monitored changes in intratumoral cytokine and chemokine levels when specific effector cells were depleted. CD8⁺ T cells, NK cells, neutrophils, and macrophages all appeared to either directly or indirectly affect the levels of various factors (Figure S3A). Our data suggested that no single cell type was entirely responsible for the increase in any given cytokine or chemokine but, likely, that a complex interdependent network of cells was involved. We focused on the neutrophil-related factors MIP-2 and G-CSF as well as the inflammatory factor IL-6, which was the most elevated inflammatory cytokine. In the case of MIP-2, depletion of NK cells, macrophages, or neutrophils led to a sharp decrease in the intratumoral concentration of this chemokine (Figure 4C), whereas G-CSF production seemed to be dependent on the presence of NK cells and macrophages (Figure 4D). Finally, IL-6 appeared to be dependent on the presence of all interrogated effector cells to various degrees (Figure 4E).

Although MIP-2 can be produced by macrophages (Wolpe et al., 1989) and neutrophils can also release MIP-2 (as well as IL-6) from pre-formed granules (Lacy and Stow, 2011), it was




Figure 3. Fc/IL-2+TA99 Induces Immune Infiltrates within B16F10 Tumors

(A) Representative immunofluorescence of immune cell infiltrates into B16F10 tumors treated with PBS or Fc/IL-2+TA99. Blue, Hoechst 33342; red, indicated lineage marker. Magnification, 20 \times . Scale bar, 100 μ m.

(B) Analysis of immune cell infiltrates into treated B16F10 tumors, normalized to total tumor mass, with lineage markers as indicated. n = 10/group. *p < 0.05, **p < 0.01 between the indicated groups. (C) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous B16F10 tumors treated with PBS and Fc/IL-2+TA99 and with depletions as indicated. n = 10/group. *p < 0.05, **p < 0.01 versus the corresponding color group in the legend. Data are mean \pm SEM. See also Figure S2.

tions (Figure 3B). We further explored the causes of this pronounced infiltration by depleting different cell types or neutralizing different factors that may be involved in boosting neutrophil infiltration or function. Both CD8⁺ T cell and NK cell depletion resulted in a statistically significant drop of intratumoral neutrophils (Figure 5A). Because NK cells modulated intratumoral MIP-2 levels via macrophages (Figures 4C and 4F), it follows that the absence of NK cells may impair neutrophil infiltration. Moreover, both CD8⁺ T cells and NK cells contributed to intratumoral interferon γ (IFN γ) (Figure S3A), which has been shown to play a role in neutrophil longevity (Pelletier et al., 2010). Indeed, intratumoral neutrophils also decreased when IFN γ was neutralized (Figure 5A).

We proceeded to investigate other potential factors promoting neutrophil infiltration. C5a of the complement system is known to be a neutrophil chemoattractant (Guo and Ward, 2005), and depletion of complement via cobra venom factor (CVF) did decrease intratumoral neutrophils (Figure 5A). Antibody-mediated neutralization of MIP-2 also led to a decrease in intratumoral neutrophils (Figure 5A), suggesting that both of these neutrophil chemoattractants play a role in neutrophil infiltration into the tumor. Furthermore, blockade of either factor during Fc/IL-2+TA99 treatment resulted in a significant reduction in treatment efficacy (Figure 5B).

Functionally, we found that intratumoral neutrophils appear to be releasing cytosolic vesicles and granules, given the high surface expression of CD63 and CD11b (Kuijpers et al., 1991) compared with neutrophils in the peripheral blood (Figure 5C). Moreover, the activation state of the neutrophils was affected by IFN γ , as observed by surface expression of CD16. Although neutrophil surface expression of CD32 remains unchanged under activating conditions, CD16 surface

interesting to note that depletion of NK cells also reduced intratumoral MIP-2 levels (Figure 4C). NK cells are not known to generate MIP-2, and, indeed, sorted intratumoral CD3⁻NK1.1⁺ NK cells showed little expression of *Cxcl2* as measured by quantitative PCR (qPCR) (Figure S3B). We hypothesized that NK cells may be modulating the production of MIP-2 by macrophages. When *Cxcl2* expression in intratumoral CD11b⁺F4/80⁺ macrophages was quantified, we observed a significant upregulation of the gene when treating with Fc/IL-2+TA99 (Figure 4F). Furthermore, with NK cell depletion, we observed a significant downregulation of *Cxcl2* expression in these macrophages (Figure 4F), suggesting that NK cells influence macrophage production of MIP-2, but solely upon Fc/IL-2+TA99 treatment.

Infiltration and Function of Neutrophils and Contribution of Respiratory Burst

A striking aspect of the synergy of Fc/IL-2+TA99 was the increase in neutrophil population above all other treatment condi-




Figure 4. Fc/IL-2+TA99 Induces an Intratumoral Cytokine Storm and Uniquely Increases Several Inflammatory and Neutrophil-Related Factors

(A and B) Luminex analysis of intratumoral concentrations of a panel of cytokines and chemokines in tumors treated with (A) PBS or Fc/IL-2+TA99 and (B) Fc/IL-2 or Fc/IL-2+TA99. Blue bars indicate factors elevated only in Fc/IL-2+TA99-treated tumors. * $p < 0.05$, ** $p < 0.01$ versus Fc/IL-2+TA99.

(C–E) Intratumoral concentrations of (C) MIP-2, (D) G-CSF, and (E) IL-6 in tumors treated with Fc/IL-2+TA99 and with depletions as indicated. $n = 10$ /group.

(F) *Cxcl2* expression in CD11b⁺F4/80⁺ macrophages sorted from tumors treated with the indicated conditions, normalized to β -2 microglobulin (*B2m*) expression. $n = 5$ /group.

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ between the indicated groups. Data are mean \pm SEM. See also Figure S3.

expression is reduced drastically (Huizinga et al., 1988; Kuijpers et al., 1991). This effect is observed with Fc/IL-2+TA99 because intratumoral neutrophils showed decreased surface CD16/32 compared with peripheral blood neutrophils, but neutralization of IFN γ partially reversed this trend (Figure 5C). Another effector function of neutrophils is the production of reactive nitrogen species via inducible nitric oxide synthase (iNOS) (Fang, 2004). We found that only Fc/IL-2+TA99 treatment led to an increase in iNOS, but those levels were reduced when either neutrophils were depleted or IFN γ was neutralized, suggesting that neutrophils may be a potential, but not necessarily exclusive, source of iNOS and that IFN γ is important for the induction of iNOS (Figure S4A). Furthermore, iNOS transcription was nearly undetectable in neutrophils from peripheral blood but was increased significantly in intratumoral neutrophils (Figure S4B). Overall, it appears that Fc/IL-2+TA99 led to the infiltration and activation of neutrophils, releasing factors that contribute to inflammation and tumor killing.

respiratory burst was from neutrophils because Fc/IL-2 alone did not result in increased neutrophil infiltration (Figure 3B). This was confirmed upon neutrophil depletion because the chemiluminescence signal was essentially unchanged (Figure S4F). Instead, we identified eosinophils as a likely source of this respiratory burst, given an increase in intratumoral IL-5 and CD11b⁺Siglec-F⁺ eosinophils with both Fc/IL-2 and Fc/IL-2+TA99 (Figures S4C and S4D). Moreover, depletion of eosinophils via anti-IL-5 antibody reduced luminol-derived chemiluminescence and diminished the therapeutic efficacy of Fc/IL-2+TA99 (Figures S4E–S4G). Given the apparent importance of the respiratory burst, we proceeded to investigate its contribution to the efficacy of Fc/IL-2+TA99 regardless of the cellular source. We employed p47phox knockout (KO) mice, which lack the p47phox subunit necessary for NADPH oxidase (Jackson et al., 1995), leading to a lack of luminol-derived chemiluminescence (Figure S4H). Indeed, the efficacy of the therapy was reduced in the treatment of these mice (Figure 5F), emphasizing the importance of respiratory burst in tumor control.




Figure 5. Neutrophil Infiltration and Function Modulated by a Suite of Immunological Elements; Oxidative Burst Contributes to Therapeutic Efficacy

(A) Analysis of CD11b $^+$ Ly-6C $^+$ Ly-6G $^+$ neutrophil infiltration into B16F10 tumors treated with PBS and Fc/IL-2+TA99 and with depletions/neutralizations as indicated, normalized to total tumor mass. Complement was depleted by CVF. $n = 10$ /group. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus Fc/IL-2+TA99.

(B) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous B16F10 tumors treated with PBS and Fc/IL-2+TA99 and with depletions/neutralizations as indicated. $n = 5$ /group. * $p < 0.05$, ** $p < 0.01$ versus Fc/IL-2+TA99.

(C) Analysis of degranulation and activation markers of neutrophils in mice treated with Fc/IL-2+TA99. $n = 5$ /group. * $p < 0.05$, *** $p < 0.001$ between the indicated groups.

(D and E) B16F10 tumors were treated with the indicated treatments and depletions/neutralizations as applicable. On days of imaging, luminol was injected, and average radiant luminescence was quantified. Representative images on day 8 are shown. In (D): (a) PBS, (b) Fc/IL-2, (c) TA99, (d) Fc/IL-2+TA99. In (E): (a) PBS, (b) Fc/IL-2+TA99, (c) Fc/IL-2+TA99+anti-CD8 α , (d) Fc/IL-2+TA99+anti-IFN γ . Arrows indicate points of treatment. $n = 5$ /group. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ Fc/IL-2+TA99 versus the corresponding color group in the legend. Scale bar, 1 cm.

(F) Tumor growth and survival curves of C57BL/6 mice or p47phox KO mice bearing subcutaneous B16F10 tumors treated with PBS or Fc/IL-2+TA99. $n = 5$ /group. * $p < 0.05$, ** $p < 0.01$ versus p47phox KO: Fc/IL-2+TA99. Data are mean \pm SEM. See also Figure S4.

Fc/IL-2 Promotes NK Cell and CD8 $^+$ T Cell Activation and Cytotoxic Function

Although NK cells and CD8 $^+$ T cells potentiated neutrophil infiltration and function, these cells themselves were likely contributing directly to therapeutic efficacy. Because Fc/IL-2 or Fc/IL-2+TA99 significantly increased intratumoral NK cells and CD8 $^+$ T cells, we proceeded to investigate how Fc/IL-2 in either case may affect their effector functions. Fc/IL-2 significantly activated intratumoral NK cells, as measured through the activation marker KLRG-1 (Huntington et al., 2007; Figure 6A). Fc/IL-2 also activated intratumoral CD8 $^+$ T cells, as measured through the activation markers CD25, CD69, and CD71 (Neckers and Cossman, 1983; Schwartz, 2003), with CD25 and CD69 being highly significant (Figure 6B and 6C), although CD71 showed a weaker trend (Figure S5A). The immune checkpoint receptors PD-1 and CTLA-4 are also markers for T cell activation (Keir et al., 2008; Walunas et al., 1994), but no differences were identified 3 days after treatment (Figure S5B and S5C). Therefore, although Fc/IL-2 alone led to significantly increased CD8 $^+$ T cell infiltration and activation in the tumor, it was apparent that T cells alone were insufficient to account for the strong tumor growth inhibition caused by Fc/IL-2+TA99 (Figure 1C).

We next wanted to investigate the cytotoxic function of NK cells and CD8 $^+$ T cells. With Fc/IL-2 or Fc/IL-2+TA99, NK

cells appeared to secrete IFN γ and degranulate, as measured through CD107a (Betts et al., 2003), although, surprisingly, both treatment conditions were comparable (Figures 6D and 6E), suggesting that the presence of an anti-tumor antibody in vivo does not directly affect these particular functions assayed 2 days after treatment. A similar observation was made for CD8 $^+$ T cells (Figures 6F and 6G), although infiltrating CD8 $^+$ T cells did exhibit reactivity against B16F10, as demonstrated by enzyme-linked immunospot (ELISPOT) (Figure S5D).

Given that CD8 $^+$ T cells produced IFN γ during anti-tumor responses, it was of interest to determine the contribution of IFN γ in controlling tumor growth. Administration of anti-IFN γ antibody demonstrated an intermediate reduction in therapeutic efficacy (Figure 6H). The previously observed increase in intratumoral tumor necrosis factor α (TNF- α) (Figure 4A) could potentially be generated by infiltrating CD8 $^+$ T cells as well, but neutralization of this cytokine did not appear to reduce the efficacy of the therapy (Figure S5E). It has also been shown that IFN γ upregulates MHC-I expression on B16F10 (Ju et al., 2005). Similarly, in our system, we confirmed, via immunohistochemistry, that an IFN γ -dependent increase of MHC-I expression on B16F10 occurred when tumors were treated with Fc/IL-2+TA99 (Figure S5F).




Figure 6. Fc/IL-2 and Fc/IL-2+TA99 Have a Comparable Effect on NK Cells and CD8+ T cells

(A–C) Analysis of NK cell or CD8+ T cell activation markers as a percentage of the intratumoral NK cell or CD8+ T cell population, respectively. The following conditions were investigated: (A) CD3+NK1.1+KLRG1+ cells, (B) CD3+CD8+CD25+ cells, (C) CD3+CD8+CD69+ cells.

(D–G) Analysis of IFNγ-producing or degranulating NK cells or CD8+ T cells as a percentage of the intratumoral NK cell or CD8+ T cell population, respectively. The following conditions were investigated: (D) CD3+NK1.1+IFNγ+ cells, (E) CD3+NK1.1+CD107a+ cells, (F) CD3+CD8+IFNγ+ cells, (G) CD3+CD8+CD107a+ cells. n = 10/group. *p < 0.05, **p < 0.01, ***p < 0.001 between the indicated groups.

(H) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous B16F10 tumors treated with PBS, Fc/IL-2+TA99, or Fc/IL-2+TA99 with anti-IFNγ antibody. n = 5/group. *p < 0.05 versus Fc/IL-2+TA99.

Data are mean ± SEM. See also Figure S5.

Adoptive Cell Transfer of pmel-1 Combined with Fc/IL-2+TA99 Confers Robust Cures and Expansion of the pmel-1 Population

Given the importance of CD8+ T cells in Fc/IL-2+TA99 therapy and the rarity of durable cures following cessation of treatment, we tested whether increasing the number of tumor specific CD8+ T cells would be sufficient to generate complete cures. To accomplish this, tumor-bearing mice received an adoptive transfer of 10⁷ pmel-1 CD8+ T cells and were treated with Fc/IL-2 and/or TA99 as described previously. Although irradiated mice treated with Fc/IL-2+TA99 or pmel-1+TA99 showed only a slight initial delay in tumor growth, mice treated with pmel-1+Fc/IL-2 showed a significant survival advantage, but all tumors eventually grew out (Figure 7A). However, all five mice treated with the triple combination of pmel-1+Fc/IL-2+TA99 experienced complete regression of their tumors, with four of five continuing to survive up to 150 days (Figure 7A). Moreover, these mice developed prominent vitiligo, suggesting that a strong melanocyte-specific T cell response was generated (Figure 7B).

To further understand the activity of the pmel-1 CD8+ T cells when combined with Fc/IL-2 and/or TA99, the experiment was repeated with pmel-1 CD8+ T cells expressing luciferase, allowing us to monitor this population by bioluminescence. Without any Fc/IL-2, the signal was very weak, suggesting that the adoptively transferred T cell population did not expand in vivo (Figure 7C). Conversely, any treatment with Fc/IL-2 resulted in cumulatively increasing luminescence (Figure 7C). In these cases, the pmel-1 CD8+ T cells appeared to survive and expand within these mice,

with a luciferase signal observed up to 140 days after the initial adoptive transfer (Figure S6A). To test the memory response of the mice cured by pmel-1+Fc/IL-2+TA99, 10⁵ B16F10 cells were injected subcutaneously into the opposite flank, and no palpable tumors were formed for up to 30 days after rechallenge (data not shown). The capability of Fc/IL-2 treatment to sustain the survival of adoptively transferred T cells was consistent with the increased infiltration and activation of endogenous T cells by such treatments (Figures 3B and 6B and 6C). Also analogous is the insufficiency of this T cell effect to produce long-term efficacy in the absence of TA99 antibody treatment. It is clear that even a huge population of melanocyte-specific CD8+ T cells sustained by Fc/IL-2 alone was insufficient to induce durable cures without the necessary contribution of an anti-tumor antigen antibody. In this case, however, neutrophils appeared to be dispensable when the third component of pmel-1 CD8+ T cells was introduced (Figure S6B).

DISCUSSION

There have been determined clinical attempts to combine anti-tumor antigen antibodies with pulsed IL-2 treatment in phase I (Bajorin et al., 1990; Bleumer et al., 2006; Eisenbeis et al., 2004; Fleming et al., 2002; Repka et al., 2003) and phase II (Khan et al., 2006; Mani et al., 2009; Poiré et al., 2010) clinical trials, all without evidence of efficacy. PEGylated IL-2 with an increased serum half-life has also been tested clinically as a monotherapy and was found not to be clinically superior (Yang et al., 1995). This suggests that a critical aspect missing may be more persistent IL-2 signaling, and, in fact, the clinical administration of anti-GD2 antibody, continuous infusion of IL-2, subcutaneous GM-CSF, and isotretinoin led to increased survival in children with high-risk neuroblastoma (Yu et al., 2010). Indeed,




Figure 7. Pmel-1+Fc/IL-2+TA99 Induces Long-Term Control of B16F10 Growth through Activation and Expansion of pmel-1 Cells

(A) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous B16F10 tumors and treated with the indicated combinations of Fc/IL-2, TA99, and 10^7 CD8⁺ pmel-1 T cells. All mice received total body irradiation 5 days after tumor inoculation. $n = 3-5/\text{group}$. ** $p < 0.01$ versus pmel-1+Fc/IL-2+TA99.

(B) Representative pictures 100 days after tumor inoculation showing vitiligo after treatment. (a) Non-treated, non-tumor-bearing, and age-matched. (b) pmel-1+Fc/IL-2+TA99-treated.

(C) Experimentally identical to (A), except CD8⁺ T cells were derived from luciferase-expressing pmel-1 mice. On days of imaging, D-luciferin was injected, and average radiant luminescence was quantified. Representative pictures on day 14 are shown: (a) pmel-1, (b) pmel-1+Fc/IL-2, (c) pmel-1+TA99, (d) pmel-1+Fc/IL-2+TA99. Arrows indicate point of treatment. $n = 5/\text{group}$. * $p < 0.05$, **** $p < 0.0001$ pmel-1 versus the corresponding color group in the legend. # $p < 0.05$, #### $p < 0.0001$ pmel-1+TA99 versus the corresponding color group in the legend. Scale bar, 1 cm.

Data are mean \pm SEM. See also Figure S6.

our own combination of an anti-tumor antigen antibody and a fusion protein bestowing prolonged IL-2 signaling, despite its greater simplicity, demonstrated significant efficacy in various syngeneic murine tumor models.

The demonstrated key components of the immune response induced by our combination immunotherapy are summarized in Figure 8. We find that our model reflects many observations of critical interactions between various effectors during administration of cancer immunotherapy reported in the literature. In syngeneic tumor models, the efficacy of antibody treatments has been shown previously to be dependent on and synergize with CD8⁺ T cell activity (Abès et al., 2010; Park et al., 2010; Stagg et al., 2011). Stimulation of CD8⁺ T cells provides not only the benefit of direct tumor killing but also the modulation of polymorphonuclear leukocytes (PMNs) for ADCC, such as through the release of cytokines like IFN γ , known to promote neutrophil activity (Pelletier et al., 2010). Although a concern with IL-2 administration could be the expansion of the intratumoral T_{reg} cell population, we find that this does not dramatically

affect the efficacy of our therapy. Indeed, despite the unchanged CD8/T_{reg} cell ratio (Figure S2D), the enhanced response by the innate immune system via the anti-tumor antigen antibody may aid in overcoming immunosuppression by T_{reg} cells. However, increased T_{reg} cell numbers may limit robust overall cures from this two-agent system.

A significant interaction between neutrophils and other effector cells in our own system was evident, because infiltration and activation of neutrophils was dependent on IFN γ and, by association, the cells that produce it. The production of the neutrophil chemoattractant MIP-2 (Wolpe et al., 1989) by macrophages has also been shown to be important for efficacy, despite reports that associate the human homolog IL-8 with increased cancer progression (Waugh and Wilson, 2008), potentially through the recruitment of N2-polarized neutrophils by T_{reg} cells or the tumors themselves (Fridlender and Albelda, 2012). However, in our system, it appears that the combination of Fc/IL-2+TA99 induces MIP-2 release by macrophages for the purpose of recruiting neutrophils, which were clearly anti-tumor in this context. In




Figure 8. Mechanistic Model of the Immune Response Induced by Fc/IL-2+TA99 against B16F10

The combination of Fc/IL-2 and anti-tumor IgG administration induces a synergistic innate and adaptive immune response. Fc/IL-2 increases the sustained exposure of NK cells and CD8⁺ T cells to IL-2 signaling, activating them. The presence of three factors—anti-tumor antibodies, Fc/IL-2, and NK cells—induces macrophages to release the neutrophil chemoattractant MIP-2. This chemokine recruits neutrophils that, expressing FcγR, likely engage the tumor via the opsonizing antibodies and perform ADCC. These and other PMNs have their cytotoxic function bolstered by IFN γ released by the activated NK cells and CD8⁺ T cells. Finally, NK cells and CD8⁺ T cells perform a direct effector function against the tumor cells as well. Overall, this complex network of immune responses results in controlled B16F10 growth during the course of treatment.

In addition, many other cytokines in the intratumoral cytokine storm induced by Fc/IL-2+TA99 are known to enhance neutrophil activity, such as TNF- α and GM-CSF (Pelletier et al., 2010) or IL-1 β and G-CSF (Colotta et al., 1992).

Interestingly, IL-6 was highly elevated as well, and, in many cases, tumor-derived IL-6 has been associated with increased disease progression (Allavena et al., 2000; Balkwill et al., 2005; Pollard, 2004). Nevertheless, IL-6 is a pleiotropic cytokine critical for transitioning from the innate to the adaptive response because it promotes CD3⁺ T cell trafficking and survival (Jones, 2005). In our immunotherapy, we observed IL-6 derivation from various effector cells, including neutrophils, which suggest that, in addition to tumor killing, neutrophils may also function to modulate the intratumoral T cell response. Overall, there are many indications that, through the administration of these two agents simultaneously, the tumor microenvironment may undergo a repolarization so that, with the presence of many inflammatory and pleiotropic cytokines and chemokines, the observed response elicited from the immune system becomes one that is anti-tumoral.

To date, little focus has been placed on eliciting strong neutrophil responses against tumors. Tumor-associated neutrophils

are often considered as pro-tumor “N2” polarized neutrophils (Fridlender and Albelda, 2012), and the immunosuppressive granulocytic subtype of myeloid derived suppressor cells also possess a similar phenotype (Gabrilovich et al., 2012). However, there are examples where neutrophils are required for antibody therapeutic effects in xenograft tumor control studies (Eisenbeis et al., 2003; Schneider-Merck et al., 2010; Siders et al., 2010). In fact, it seems intuitive to utilize the underappreciated neutrophil to mount an anti-tumor response, given that they are the most abundant of circulating leukocytes, and, in other forms of immune challenge, neutrophils are the first responders, inducing massive cell killing. Moreover, neutrophils have been shown to release chemotactic factors to recruit other effector cells (Lillard et al., 1999) and produce cytokines that can modulate T cells (Cassatella, 1995). Although a robust T cell response is ultimately required for tumor rejection and immunological memory, the innate arm of the immune system may provide the necessary support to boost existing T cell-focused immunotherapies. This was demonstrated when we combined the existing Fc/IL-2+TA99 with adoptive T cell transfer.

We surmised and confirmed that creating an overwhelming melanocyte-specific CD8⁺ T cell response via adoptive cell transfer provided the sustained effector function necessary for complete cures in combination with Fc/IL-2+TA99. Although Fc/IL-2 treatment alone maintained the survival of adoptively transferred pmel-1 cells, it is significant that, in the absence of the antibody to bridge tumors to innate effectors, all pmel-1+Fc/IL-2-treated mice ultimately succumbed to the tumor. Therefore, in this system, antibody-mediated effects remained critical for providing tumor killing that contributed to long-term T cell-mediated efficacy.

In this study, we uncovered a mechanism of tumor control induced by Fc/IL-2+TA99 that differs qualitatively from a predominant importance of NK cells, a view that has previously been held for combination treatments using anti-tumor antibodies and IL-2. In particular, the potential for a strong synergistic interaction of T cells and neutrophils has been noted in infectious and autoimmune diseases (Müller et al., 2009) but has been largely unappreciated as a contributor to tumor immunotherapy (Buonocore et al., 2008). Therefore, although work in the immunotherapy space has traditionally been focused on boosting only an anti-tumor T cell or NK cell response, a more powerful approach may be to identify ways to conscript neutrophils and other innate effector cells to synergize with existing immunotherapies that stimulate T cell activity.

EXPERIMENTAL PROCEDURES

More detailed procedures can be found in the [Supplemental Experimental Procedures](#).

Mice

C57BL/6NTac mice (Taconic), C3H/HeNTac mice (Taconic), and pmel-1 (B6.Cg-Thy1a/Cy Tg(Tcr α Tcr β)Rest/J) mice (The Jackson Laboratory) were aged between 6–10 weeks before tumor induction. All animal work was conducted under the approval of the Massachusetts Institute of Technology (MIT) Division of Comparative Medicine in accordance with federal, state, and local guidelines.

Tumor Inoculation and Treatment

For induction of B16F10 tumors, 10⁶ cells in 100 μ l of PBS were injected subcutaneously into the flanks of C57BL/6 mice. Retro-orbital injection of PBS,

IL-2 (6 μ g, PeproTech), Fc/IL-2 (25 μ g), MSA/IL-2 (30 μ g), and/or TA99 (100 μ g) was done on days 6, 12, 18, 24, and 30 after tumor inoculation for a total of five treatments. Additional details, models, depletions, neutralizations, and adoptive cell transfer are described in the [Supplemental Experimental Procedures](#).

Flow Cytometry

Tumor inoculation and treatment were done as described previously. Single-cell suspensions were prepared, stained, and analyzed as described in the [Supplemental Experimental Procedures](#).

Intratumoral Cytokine Analysis

Tumor inoculation and treatment were done as described previously. Tumors were homogenized, and protein concentrations were normalized and evaluated in triplicate using the Mouse 32-Plex cytokine/chemokine panel luminex assay as performed by Eve Technologies. More detailed information can be found in the [Supplemental Experimental Procedures](#).

Statistics

Statistical analysis was performed with GraphPad Prism 5 software (GraphPad). More detailed information can be found in the [Supplemental Experimental Procedures](#).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.ccell.2015.03.004>.

AUTHOR CONTRIBUTIONS

E.F.Z., S.A.G., and C.F.O. designed and performed experiments. B.H.K., R.S., M.J.K., K.D.M., A.A., and R.T.W. performed experiments. M.C.M. provided analysis of histology. M.T.S., J.S.K., M.B.Y., D.J.I., L.M.W., and G.D. provided critical reagents and advice. E.F.Z., S.A.G., C.F.O., and K.D.W. interpreted data and wrote the manuscript.

ACKNOWLEDGMENTS

We thank Dr. Bronson for pathological analysis and the staff of the Swanson Biotechnology Center at the Koch Institute for technical assistance. This study was supported by National Cancer Institute Grant NCI CA174795. E.F.Z. was supported by the NIH/NIGMS Biotechnology Training Program. S.A.G. and C.F.O. were supported by a NSF graduate research fellowship.

Received: November 21, 2013

Revised: October 19, 2014

Accepted: March 9, 2015

Published: April 13, 2015

REFERENCES

Abès, R., Gélizé, E., Fridman, W.H., and Teillaud, J.-L. (2010). Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. *Blood* *116*, 926–934.

Allavena, P., Sica, A., Vecchi, A., Locati, M., Sozzani, S., and Mantovani, A. (2000). The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. *Immunol. Rev.* *177*, 141–149.

Anderson, C.L., Chaudhury, C., Kim, J., Bronson, C.L., Wani, M.A., and Mohanty, S. (2006). Perspective—FcRn transports albumin: relevance to immunology and medicine. *Trends Immunol.* *27*, 343–348.

Bajorin, D.F., Chapman, P.B., Wong, G., Coit, D.G., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Urmacher, C., Dantes, L., Templeton, M.A., et al. (1990). Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. *Cancer Res.* *50*, 7490–7495.

Baley, P.A., Yoshida, K., Qian, W., Sehgal, I., and Thompson, T.C. (1995). Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. *J. Steroid Biochem. Mol. Biol.* *52*, 403–413.

Balkwill, F., Charles, K.A., and Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* *7*, 211–217.

Baudino, L., Shinohara, Y., Nimmerjahn, F., Furukawa, J., Nakata, M., Martínez-Soria, E., Petry, F., Ravetch, J.V., Nishimura, S., and Izui, S. (2008). Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. *J. Immunol.* *181*, 6664–6669.

Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., and Koup, R.A. (2003). Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. *J. Immunol. Methods* *281*, 65–78.

Bleumer, I., Oosterwijk, E., Oosterwijk-Wakka, J.C., Völler, M.C., Melchior, S., Warnaar, S.O., Mala, C., Beck, J., and Mulders, P.F.A. (2006). A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. *J. Urol.* *175*, 57–62.

Buonocore, S., Haddou, N.O., Moore, F., Florquin, S., Paulart, F., Heirman, C., Thielemans, K., Goldman, M., and Flamand, V. (2008). Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L. *J. Leukoc. Biol.* *84*, 713–720.

Carson, W.E., Parihar, R., Lindemann, M.J., Personeni, N., Dierksheide, J., Meropol, N.J., Baselga, J., and Caligiuri, M.A. (2001). Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. *Eur. J. Immunol.* *31*, 3016–3025.

Cassatella, M.A. (1995). The production of cytokines by polymorphonuclear neutrophils. *Immunol. Today* *16*, 21–26.

Clemente, C.G., Mihm, M.C., Jr., Bufalino, R., Zurrada, S., Collini, P., and Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *Cancer* *77*, 1303–1310.

Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat. Med.* *6*, 443–446.

Colotta, F., Re, F., Polentarutti, N., Sozzani, S., and Mantovani, A. (1992). Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. *Blood* *80*, 2012–2020.

Dyall, R., Vasovic, L.V., Clynes, R.A., and Nikolić-Zugčić, J. (1999). Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. *Eur. J. Immunol.* *29*, 30–37.

Eisenbeis, C.F., Caligiuri, M.A., and Byrd, J.C. (2003). Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? *Clin. Cancer Res.* *9*, 5810–5812.

Eisenbeis, C.F., Grainger, A., Fischer, B., Baiocchi, R.A., Carrodegua, L., Roychowdhury, S., Chen, L., Banks, A.L., Davis, T., Young, D., et al. (2004). Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. *Clin. Cancer Res.* *10*, 6101–6110.

Fang, F.C. (2004). Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. *Nat. Rev. Microbiol.* *2*, 820–832.

Feau, S., Arens, R., Togher, S., and Schoenberger, S.P. (2011). Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. *Nat. Immunol.* *12*, 908–913.

Ferris, R.L., Jaffee, E.M., and Ferrone, S. (2010). Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. *J. Clin. Oncol.* *28*, 4390–4399.

Fleming, G.F., Meropol, N.J., Rosner, G.L., Hollis, D.R., Carson, W.E., 3rd, Caligiuri, M., Mortimer, J., Tkaczuk, K., Parihar, R., Schilsky, R.L., and Ratain, M.J. (2002). A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. *Clin. Cancer Res.* *8*, 3718–3727.

Fridlender, Z.G., and Albelda, S.M. (2012). Tumor-associated neutrophils: friend or foe? *Carcinogenesis* *33*, 949–955.

Gabrilovich, D.I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. *Nat. Rev. Immunol.* *12*, 253–268.

- Gross, S., Gammon, S.T., Moss, B.L., Rauch, D., Harding, J., Heinecke, J.W., Ratner, L., and Piwnica-Worms, D. (2009). Bioluminescence imaging of myeloperoxidase activity in vivo. *Nat. Med.* *15*, 455–461.
- Guo, R.-F., and Ward, P.A. (2005). Role of C5a in inflammatory responses. *Annu. Rev. Immunol.* *23*, 821–852.
- Huizinga, T.W.J., van der Schoot, C.E., Jost, C., Klaassen, R., Kleijer, M., van dem Borne, A.E.G.K., Roos, D., and Tetteroo, P.A.T. (1988). The PI-linked receptor FcR3 is released on stimulation of neutrophils. *Nature* *333*, 667–669.
- Huntington, N.D., Tabarias, H., Fairfax, K., Brady, J., Hayakawa, Y., Degli-Esposti, M.A., Smyth, M.J., Tarlinton, D.M., and Nutt, S.L. (2007). NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. *J. Immunol.* *178*, 4764–4770.
- Jackson, S.H., Gallin, J.I., and Holland, S.M. (1995). The p47phox mouse knock-out model of chronic granulomatous disease. *J. Exp. Med.* *182*, 751–758.
- Jones, S.A. (2005). Directing transition from innate to acquired immunity: defining a role for IL-6. *J. Immunol.* *175*, 3463–3468.
- Ju, S.-A., Lee, S.-C., Kwon, T.-H., Heo, S.-K., Park, S.-M., Paek, H.-N., Suh, J.-H., Cho, H.R., Kwon, B., Kwon, B.S., and Kim, B.S. (2005). Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. *Immunol. Cell Biol.* *83*, 344–351.
- June, C.H. (2007). Principles of adoptive T cell cancer therapy. *J. Clin. Invest.* *117*, 1204–1212.
- Kalia, V., Sarkar, S., Subramaniam, S., Haining, W.N., Smith, K.A., and Ahmed, R. (2010). Prolonged interleukin-2 α expression on virus-specific CD8⁺ T cells favors terminal-effector differentiation in vivo. *Immunity* *32*, 91–103.
- Keir, M.E., Butte, M.J., Freeman, G.J., and Sharpe, A.H. (2008). PD-1 and its ligands in tolerance and immunity. *Annu. Rev. Immunol.* *26*, 677–704.
- Khan, K.D., Emmanouilides, C., Benson, D.M., Jr., Hurst, D., Garcia, P., Michelson, G., Milan, S., Ferketich, A.K., Piro, L., Leonard, J.P., et al. (2006). A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. *Clin. Cancer Res.* *12*, 7046–7053.
- Konrad, M.W., Hemstreet, G., Hersh, E.M., Mansell, P.W.A., Mertelsmann, R., Koltitz, J.E., and Bradley, E.C. (1990). Pharmacokinetics of recombinant interleukin 2 in humans. *Cancer Res.* *50*, 2009–2017.
- Kuijpers, T.W., Tool, A.T., van der Schoot, C.E., Ginsel, L.A., Onderwater, J.J., Roos, D., and Verhoeven, A.J. (1991). Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. *Blood* *78*, 1105–1111.
- Lacy, P., and Stow, J.L. (2011). Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. *Blood* *118*, 9–18.
- Liao, W., Lin, J.-X., and Leonard, W.J. (2013). Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. *Immunity* *38*, 13–25.
- Lillard, J.W., Jr., Boyaka, P.N., Chertov, O., Oppenheim, J.J., and McGhee, J.R. (1999). Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. *Proc. Natl. Acad. Sci. USA* *96*, 651–656.
- Mani, A., Roda, J., Young, D., Caligiuri, M.A., Fleming, G.F., Kaufman, P., Brufsky, A., Ottman, S., Carson, W.E., 3rd, and Shapiro, C.L. (2009). A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. *Breast Cancer Res. Treat.* *117*, 83–89.
- Müller, I., Munder, M., Kropf, P., and Hänsch, G.M. (2009). Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? *Trends Immunol.* *30*, 522–530.
- Neckers, L.M., and Cossman, J. (1983). Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. *Proc. Natl. Acad. Sci. USA* *80*, 3494–3498.
- Overwijk, W.W. (2005). Breaking tolerance in cancer immunotherapy: time to ACT. *Curr. Opin. Immunol.* *17*, 187–194.
- Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al. (2010). The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. *Cancer Cell* *18*, 160–170.
- Pelletier, M., Micheletti, A., and Cassatella, M.A. (2010). Modulation of human neutrophil survival and antigen expression by activated CD4⁺ and CD8⁺ T cells. *J. Leukoc. Biol.* *88*, 1163–1170.
- Pipkin, M.E., Sacks, J.A., Cruz-Guilloty, F., Lichtenheld, M.G., Bevan, M.J., and Rao, A. (2010). Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. *Immunity* *32*, 79–90.
- Poiré, X., Kline, J., Grinblatt, D., Zimmerman, T., Conner, K., Muhs, C., Gajewski, T., Van Besien, K., and Smith, S.M. (2010). Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. *Leuk. Lymphoma* *51*, 1241–1250.
- Pollard, J.W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. *Nat. Rev. Cancer* *4*, 71–78.
- Rao, B.M., Driver, I., Lauffenburger, D.A., and Wittrup, K.D. (2005). High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. *Biochemistry* *44*, 10696–10701.
- Repka, T., Chiorean, E.G., Gay, J., Herwig, K.E., Kohl, V.K., Yee, D., and Miller, J.S. (2003). Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. *Clin. Cancer Res.* *9*, 2440–2446.
- Schneider-Merck, T., Lammerts van Bueren, J.J., Berger, S., Rossen, K., van Berkel, P.H.C., Derer, S., Beyer, T., Lohse, S., Bleeker, W.K., Peipp, M., et al. (2010). Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. *J. Immunology* *184*, 512–520.
- Schwartz, R.H. (2003). T cell anergy. *Annu. Rev. Immunol.* *21*, 305–334.
- Siders, W.M., Shields, J., Garron, C., Hu, Y., Boutin, P., Shankara, S., Weber, W., Roberts, B., and Kaplan, J.M. (2010). Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. *Leuk. Lymphoma* *51*, 1293–1304.
- Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M., and Fox, J.A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). *Semin. Oncol.* *26* (4, Suppl 12), 60–70.
- Stagg, J., Johnstone, R.W., and Smyth, M.J. (2007). From cancer immunosurveillance to cancer immunotherapy. *Immunol. Rev.* *220*, 82–101.
- Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., Teng, M.W., and Smyth, M.J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. *Proc. Natl. Acad. Sci. USA* *108*, 7142–7147.
- Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., and Panoskaltis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. *N. Engl. J. Med.* *355*, 1018–1028.
- van Elsas, A., Hurwitz, A.A., and Allison, J.P. (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J. Exp. Med.* *190*, 355–366.
- Vasović, L.V., Dyal, R., Clynes, R.A., Ravetch, J.V., and Nikolić-Zugic, J. (1997). Synergy between an antibody and CD8⁺ cells in eliminating an established tumor. *Eur. J. Immunol.* *27*, 374–382.
- Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., and Bluestone, J.A. (1994). CTLA-4 can function as a negative regulator of T cell activation. *Immunity* *1*, 405–413.
- Wang, S., Astsaturov, I.A., Bingham, C.A., McCarthy, K.M., von Mehren, M., Xu, W., Alpaugh, R.K., Tang, Y., Littlefield, B.A., Hawkins, L.D., et al. (2012). Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. *Cancer Immunol. Immunother.* *61*, 49–61.
- Ward, P.L., Koepfen, H., Hurteau, T., and Schreiber, H. (1989). Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. *J. Exp. Med.* *170*, 217–232.

- Waugh, D.J.J., and Wilson, C. (2008). The interleukin-8 pathway in cancer. *Clin. Cancer Res.* 14, 6735–6741.
- Weiner, L.M., Dhodapkar, M.V., and Ferrone, S. (2009). Monoclonal antibodies for cancer immunotherapy. *Lancet* 373, 1033–1040.
- Weng, W.-K., and Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J. Clin. Oncol.* 21, 3940–3947.
- Winkler, U., Jensen, M., Mancke, O., Schulz, H., Diehl, V., and Engert, A. (1999). Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). *Blood* 94, 2217–2224.
- Wolpe, S.D., Sherry, B., Juers, D., Davatelis, G., Yurt, R.W., and Cerami, A. (1989). Identification and characterization of macrophage inflammatory protein 2. *Proc. Natl. Acad. Sci. USA* 86, 612–616.
- Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Parkinson, D.R., Marincola, F.M., Weber, J.S., Seipp, C.A., White, D.E., and Rosenberg, S.A. (1995). The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. *Cancer* 76, 687–694.
- Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., et al.; Children's Oncology Group (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. *N. Engl. J. Med.* 363, 1324–1334.
- Zhang, H., Zhang, S., Cheung, N.-K.V., Ragupathi, G., and Livingston, P.O. (1998). Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. *Cancer Res.* 58, 2844–2849.